SK Biopharmaceuticals Co., Ltd. (KRX:326030)

South Korea flag South Korea · Delayed Price · Currency is KRW
101,100
-400 (-0.39%)
At close: Sep 29, 2025
-4.71%
Market Cap 7.95T
Revenue (ttm) 620.28B
Net Income (ttm) 255.99B
Shares Out 78.31M
EPS (ttm) 3,268.81
PE Ratio 31.05
Forward PE 40.42
Dividend n/a
Ex-Dividend Date n/a
Volume 137,447
Average Volume 201,153
Open 102,500
Previous Close 101,500
Day's Range 100,500 - 102,900
52-Week Range 86,900 - 130,000
Beta 0.89
RSI 40.93
Earnings Date Nov 5, 2025

About SK Biopharmaceuticals

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, w... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 246
Stock Exchange Korea Stock Exchange
Ticker Symbol 326030
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.